Novo Nordisk A/S $NVO Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 49.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 237,978 shares of the company’s stock after selling 237,049 shares during the period. Commonwealth Equity Services LLC’s holdings in Novo Nordisk A/S were worth $13,205,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in NVO. True Wealth Design LLC grew its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the period. NewSquare Capital LLC grew its holdings in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $37,000. Maseco LLP purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $39,000. Finally, Copeland Capital Management LLC raised its holdings in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.6%

Shares of NVO stock opened at $58.85 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The firm’s 50 day moving average price is $49.65 and its two-hundred day moving average price is $55.29. The stock has a market cap of $262.78 billion, a price-to-earnings ratio of 17.11 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Amazon Pharmacy began offering Novo Nordisk’s new Wegovy pill through insurance plans and a cash-pay option, expanding U.S. distribution and making the first-ever oral GLP‑1 from Novo more accessible to patients — a direct demand and revenue catalyst. Amazon Pharmacy offers Novo Nordisk’s Wegovy pill
• Positive Sentiment: Major retail pharmacy availability reported by CNBC/MSN increases distribution visibility and could shorten the time to volume adoption for the Wegovy pill, supporting revenue upside versus slower clinic-based rollouts. Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
• Positive Sentiment: Investor research pieces flag Novo as a top pick for 2026 and highlight the FDA‑approved Wegovy pill as a growth catalyst; analysts note robust margins and free cash flow potential (but also cite pricing and competition risks). This supportive analyst tone can lift sentiment and trading interest. Novo Nordisk: A Pill For Growth
• Neutral Sentiment: The JPMorgan Healthcare Conference will put pharma pipeline updates and potential M&A back in focus; Novo may benefit from heightened investor attention but concrete impacts depend on announcements made at the event. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Marketing and PR activities — e.g., a public conversation on weight stigma at a major NYC commuter hub — help brand and patient engagement but are unlikely to move near-term revenue materially. Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub
• Neutral Sentiment: Recent price commentary (Zacks note on a modest prior-day gain) reflects momentum but is informational rather than a fundamental driver. Novo Nordisk (NVO) Surpasses Market Returns

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating for the company. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Finally, HSBC reissued a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $56.21.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.